secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001104659-25-034793
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents appoints Thomas Shannon as VP of Marketing for North America ahead of DrugSorb-ATR launch
--------------------------------------------------------------------------------

- Thomas Shannon appointed VP of Marketing, North America; will lead strategy for DrugSorb-ATR in U.S. and Canada.
- Shannon has 25+ years commercializing cardiovascular and critical care devices at Fresenius, Getinge, Medtronic.
- DrugSorb-ATR is an FDA Breakthrough device for perioperative bleeding in CABG patients on Brilinta; regulatory decisions expected in 2025.
- CEO Dr. Phillip Chan highlights Shannon's expertise as 'invaluable' for commercialization as company awaits FDA/Health Canada approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925034793/0001104659-25-034793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925034793/tm2512296d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-034793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer